secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001326110-23-000023
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio provides N-803 BLA update with May 23 PDUFA, reports NSCLC OS data, and notes S1800D closure
--------------------------------------------------------------------------------

- BLA for N-803+BCG in BCG-unresponsive NMIBC with CIS; PDUFA date May 23, 2023; approval uncertain.
- QUILT 3.055 NSCLC pooled analysis (N=86) shows median OS 13.9 months vs historical 6-7.5 months.
- SWOG/NCI S1800D study (N-803+pembrolizumab) closed early for not meeting 60% disease control at 12 weeks.
- Company exploring partnering for N-803 intravesical commercialization and potential financing from Executive Chairman.
- Board appointed Cheryl L. Cohen as Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000023/0001326110-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000023/ibrx-20230320.htm
  HTML page:      https://secwatch.observer/filing/0001326110-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer